Hanmi Pharm, DKSH sign deal to sell three incrementally modified drugs

Published: 2013-07-19 06:57:00

Updated: 2013-07-19 06:57:00

Hanmi Pharmaceuticals Co. said Wednesday it established a strategic partnership with DKSH, the leading Market Expansion Services Group with a focus on Asia.

Under the exclusive distribution agreement, DKSH will market Hanmi’s three incrementally modified drugs (IMDs) over the next ten years: A...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK